Neda Feizi, Mahsa Mohamadzadeh-Nabiei, Hadi Vahedi, Shadi Farabi Maleki, Ali Jafarizadeh
{"title":"促红细胞生成素在甲醇诱导的视神经病变中的治疗作用：系统综述。","authors":"Neda Feizi, Mahsa Mohamadzadeh-Nabiei, Hadi Vahedi, Shadi Farabi Maleki, Ali Jafarizadeh","doi":"10.1007/s40199-024-00551-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Despite various therapeutic attempts, an approved treatment for Methanol-induced optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known as an erythropoietic cytokine, possesses various non-hematopoietic properties that make it a candidate for MION treatment. This systematic review aims to assess the potential therapeutic role of erythropoietin in MION.</p><p><strong>Method: </strong>We systematically searched English and Persian databases including PubMed, Scopus, Embase, Web of Science, and Scientific Information Database (SID) as of July 2024. Two independent authors screened the articles based on their titles, abstracts, and full texts to finalize the included articles in this study. The selected articles underwent quality assessments via the Joanna Briggs Institute (JBI) checklists.</p><p><strong>Results: </strong>Out of 139 studies identified in the databases, 11 were finally included in the analysis. These studies encompassed 212 participants, with 192 receiving erythropoietin treatment. Visual acuity (VA) improved in 184 patients, with improvements ranging from no light perception to full vision recovery, or minor enhancements such as an improvement from 1.75 ± 0.72 to 1.32 ± 0.79 LogMAR. Only 8 patients showed no change or experienced deterioration. Additionally, 21 cases exhibited a reduction in retinal nerve fiber layer thickness, with one showing a reduction towards the normal range.</p><p><strong>Conclusion: </strong>This review highlights erythropoietin's positive impact on VA in patients with MION. However, simultaneous use of erythropoietin and corticosteroids in studies without control groups complicates evaluating erythropoietin's independent efficacy. Future research should involve large, controlled trials to clarify erythropoietin's role and establish it as a standard treatment.</p><p><strong>Prospero registration number: </strong>CRD42023485772.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":"33 1","pages":"2"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607285/pdf/","citationCount":"0","resultStr":"{\"title\":\"Therapeutic role of erythropoietin in methanol induced optic neuropathy: a systematic review.\",\"authors\":\"Neda Feizi, Mahsa Mohamadzadeh-Nabiei, Hadi Vahedi, Shadi Farabi Maleki, Ali Jafarizadeh\",\"doi\":\"10.1007/s40199-024-00551-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Despite various therapeutic attempts, an approved treatment for Methanol-induced optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known as an erythropoietic cytokine, possesses various non-hematopoietic properties that make it a candidate for MION treatment. This systematic review aims to assess the potential therapeutic role of erythropoietin in MION.</p><p><strong>Method: </strong>We systematically searched English and Persian databases including PubMed, Scopus, Embase, Web of Science, and Scientific Information Database (SID) as of July 2024. Two independent authors screened the articles based on their titles, abstracts, and full texts to finalize the included articles in this study. The selected articles underwent quality assessments via the Joanna Briggs Institute (JBI) checklists.</p><p><strong>Results: </strong>Out of 139 studies identified in the databases, 11 were finally included in the analysis. These studies encompassed 212 participants, with 192 receiving erythropoietin treatment. Visual acuity (VA) improved in 184 patients, with improvements ranging from no light perception to full vision recovery, or minor enhancements such as an improvement from 1.75 ± 0.72 to 1.32 ± 0.79 LogMAR. Only 8 patients showed no change or experienced deterioration. Additionally, 21 cases exhibited a reduction in retinal nerve fiber layer thickness, with one showing a reduction towards the normal range.</p><p><strong>Conclusion: </strong>This review highlights erythropoietin's positive impact on VA in patients with MION. However, simultaneous use of erythropoietin and corticosteroids in studies without control groups complicates evaluating erythropoietin's independent efficacy. Future research should involve large, controlled trials to clarify erythropoietin's role and establish it as a standard treatment.</p><p><strong>Prospero registration number: </strong>CRD42023485772.</p>\",\"PeriodicalId\":10888,\"journal\":{\"name\":\"DARU Journal of Pharmaceutical Sciences\",\"volume\":\"33 1\",\"pages\":\"2\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-11-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607285/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"DARU Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40199-024-00551-w\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"DARU Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40199-024-00551-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的：尽管有各种治疗尝试，甲醇诱导的视神经病变（MION），一种视力威胁疾病，仍然缺乏一种被批准的治疗方法。促红细胞生成素是一种促红细胞生成细胞因子，具有多种非造血特性，使其成为MION治疗的候选药物。本系统综述旨在评估促红细胞生成素在MION中的潜在治疗作用。方法：系统检索截至2024年7月的英文和波斯语数据库，包括PubMed、Scopus、Embase、Web of Science和Scientific Information Database （SID）。两位独立作者根据文章标题、摘要和全文对文章进行筛选，最终确定纳入本研究的文章。入选的文章通过乔安娜布里格斯研究所（JBI）的检查表进行了质量评估。结果：在数据库中确定的139项研究中，有11项最终被纳入分析。这些研究包括212名参与者，其中192人接受促红细胞生成素治疗。184例患者的视力（VA）得到改善，改善范围从无光感知到完全视力恢复，或从1.75±0.72到1.32±0.79 LogMAR的轻微改善。仅有8例患者无变化或病情恶化。此外，21例视网膜神经纤维层厚度减少，其中1例显示向正常范围减少。结论：本综述强调了促红细胞生成素对MION患者VA的积极影响。然而，在没有对照组的研究中同时使用促红细胞生成素和皮质类固醇使评估促红细胞生成素的独立疗效复杂化。未来的研究应该包括大规模的对照试验，以阐明促红细胞生成素的作用，并将其作为一种标准治疗方法。普洛斯彼罗注册号：CRD42023485772。
Therapeutic role of erythropoietin in methanol induced optic neuropathy: a systematic review.
Purpose: Despite various therapeutic attempts, an approved treatment for Methanol-induced optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known as an erythropoietic cytokine, possesses various non-hematopoietic properties that make it a candidate for MION treatment. This systematic review aims to assess the potential therapeutic role of erythropoietin in MION.
Method: We systematically searched English and Persian databases including PubMed, Scopus, Embase, Web of Science, and Scientific Information Database (SID) as of July 2024. Two independent authors screened the articles based on their titles, abstracts, and full texts to finalize the included articles in this study. The selected articles underwent quality assessments via the Joanna Briggs Institute (JBI) checklists.
Results: Out of 139 studies identified in the databases, 11 were finally included in the analysis. These studies encompassed 212 participants, with 192 receiving erythropoietin treatment. Visual acuity (VA) improved in 184 patients, with improvements ranging from no light perception to full vision recovery, or minor enhancements such as an improvement from 1.75 ± 0.72 to 1.32 ± 0.79 LogMAR. Only 8 patients showed no change or experienced deterioration. Additionally, 21 cases exhibited a reduction in retinal nerve fiber layer thickness, with one showing a reduction towards the normal range.
Conclusion: This review highlights erythropoietin's positive impact on VA in patients with MION. However, simultaneous use of erythropoietin and corticosteroids in studies without control groups complicates evaluating erythropoietin's independent efficacy. Future research should involve large, controlled trials to clarify erythropoietin's role and establish it as a standard treatment.
期刊介绍：
DARU Journal of Pharmaceutical Sciences is a peer-reviewed journal published on behalf of Tehran University of Medical Sciences. The journal encompasses all fields of the pharmaceutical sciences and presents timely research on all areas of drug conception, design, manufacture, classification and assessment.
The term DARU is derived from the Persian name meaning drug or medicine. This journal is a unique platform to improve the knowledge of researchers and scientists by publishing novel articles including basic and clinical investigations from members of the global scientific community in the forms of original articles, systematic or narrative reviews, meta-analyses, letters, and short communications.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
